Biovica provides time-plan for FDA submission

2022-02-07 21:48

Biovica, active in cancer diagnostics, today announces that it has received full feedback from the FDA on its updated 510(k)-application enabling a clear plan for the submission process. Biovica is now aiming for submission in May 2022.

As previously announced, Biovica has been waiting for required feedback from the US Food and Drug Administration (FDA) to be able to submit its updated 510(k)-application by a so-called complete response letter. The delay at the FDA was caused by the pandemic situation.

Now, Biovica has received feedback and has been informed that that there is only one question outstanding before the company can submit its updated application. Biovica has agreed with the FDA on which information Biovica needs to provide and is confident in being able to produce the required information for submission in May.

“This is great news as we now know which information we need to provide in order to complete our updated application. We believe that the interactive process that we have gone through with the FDA will be to our benefit in the review following the submission.”, says Anders Rylander, CEO of Biovica.

After submitting the application to the FDA, the expected outcome is either approval (clearance) or a request to submit more information.


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program